Cas:871334-35-9 N-[3,5-bis(trifluoroMethyl)phenyl]-N’-[(9R)-10,11-dihydro-6′-Methoxycinchonan-9-yl]- Thiourea manufacturer & supplier

Chemical Name:N-[3,5-bis(trifluoroMethyl)phenyl]-N’-[(9R)-10,11-dihydro-6′-Methoxycinchonan-9-yl]- Thiourea

CAS.NO:871334-35-9

Synonyms:1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(4β,9R)-6′-methoxy-10,11-dihydrocinchonan-9-yl]thiourea;Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N’-[(4β,9R)-10,11-dihydro-6′-methoxycinchonan-9-yl]-

Molecular Formula:C₂₉H₃₀F₆N₄OS

Molecular Weight:596.630

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:600.8±65.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.606

PSA:

Exact Mass:596.204468

LogP:7.65

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(4β,9R)-6′-methoxy-10,11-dihydrocinchonan-9-yl]thiourea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N’-[(4β,9R)-10,11-dihydro-6′-methoxycinchonan-9-yl]- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N’-[(4β,9R)-10,11-dihydro-6′-methoxycinchonan-9-yl]- Use and application,1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(4β,9R)-6′-methoxy-10,11-dihydrocinchonan-9-yl]thiourea technical grade,usp/ep/jp grade.

Related News: The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. N-[3,5-bis(trifluoroMethyl)phenyl]-N’-[(9R)-10,11-dihydro-6′-Methoxycinchonan-9-yl]- Thiourea manufacturer Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. N-[3,5-bis(trifluoroMethyl)phenyl]-N’-[(9R)-10,11-dihydro-6′-Methoxycinchonan-9-yl]- Thiourea supplier The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added. N-[3,5-bis(trifluoroMethyl)phenyl]-N’-[(9R)-10,11-dihydro-6′-Methoxycinchonan-9-yl]- Thiourea vendor Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. N-[3,5-bis(trifluoroMethyl)phenyl]-N’-[(9R)-10,11-dihydro-6′-Methoxycinchonan-9-yl]- Thiourea factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.